Gene expression profiling of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Issue 5 (9th April 2014)
- Record Type:
- Journal Article
- Title:
- Gene expression profiling of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Issue 5 (9th April 2014)
- Main Title:
- Gene expression profiling of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways
- Authors:
- Kato, Harumi
Karube, Kennosuke
Yamamoto, Kazuhito
Takizawa, Jun
Tsuzuki, Shinobu
Yatabe, Yasushi
Kanda, Teru
Katayama, Miyuki
Ozawa, Yukiyasu
Ishitsuka, Kenji
Okamoto, Masataka
Kinoshita, Tomohiro
Ohshima, Koichi
Nakamura, Shigeo
Morishima, Yasuo
Seto, Masao - Abstract:
- <abstract abstract-type="main" id="cas12389-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly (EBV[+]DLBCL‐E) is classified as a subtype of DLBCL. Until now, its molecular pathogenesis has remained unknown. To identify pathways characteristic of EBV(+)DLBCL‐E, gene expression profiling of five EBV(+)DLBCL‐E and seven EBV‐negative DLBCL (EBV[−]DLBCL) cases was undertaken using human oligonucleotide microarray analysis. Gene set enrichment analysis and gene ontology analysis showed that gene sets of the Janus kinase‐signal transducer and activator of transcription (JAK‐STAT) and nuclear factor kappa B (NF‐κB) pathways were enriched in EBV(+)DLBCL‐E cases. To confirm the results of the expression profiles, <italic>in vitro</italic> analysis was performed. Expression profiling analysis showed that high activation of the JAK‐STAT and NF‐κB pathways was induced by EBV infection into DLBCL cell lines. Activation of the NF‐κB pathway was confirmed in EBV‐infected cell lines using an electrophoretic mobility shift assay. Western blot analysis revealed an increased protein expression level of phosphorylated signal transducer and activator of transcription 3 (STAT3) in an EBV‐infected cell line. Protein expression of phosphorylated STAT3 was frequently observed in lymphoma cells of EBV(+)DLBCL‐E clinical samples using immunohistochemistry (EBV[+]DLBCL‐E: 80.0%<abstract abstract-type="main" id="cas12389-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly (EBV[+]DLBCL‐E) is classified as a subtype of DLBCL. Until now, its molecular pathogenesis has remained unknown. To identify pathways characteristic of EBV(+)DLBCL‐E, gene expression profiling of five EBV(+)DLBCL‐E and seven EBV‐negative DLBCL (EBV[−]DLBCL) cases was undertaken using human oligonucleotide microarray analysis. Gene set enrichment analysis and gene ontology analysis showed that gene sets of the Janus kinase‐signal transducer and activator of transcription (JAK‐STAT) and nuclear factor kappa B (NF‐κB) pathways were enriched in EBV(+)DLBCL‐E cases. To confirm the results of the expression profiles, <italic>in vitro</italic> analysis was performed. Expression profiling analysis showed that high activation of the JAK‐STAT and NF‐κB pathways was induced by EBV infection into DLBCL cell lines. Activation of the NF‐κB pathway was confirmed in EBV‐infected cell lines using an electrophoretic mobility shift assay. Western blot analysis revealed an increased protein expression level of phosphorylated signal transducer and activator of transcription 3 (STAT3) in an EBV‐infected cell line. Protein expression of phosphorylated STAT3 was frequently observed in lymphoma cells of EBV(+)DLBCL‐E clinical samples using immunohistochemistry (EBV[+]DLBCL‐E: 80.0% [<italic>n</italic> = 20/25] versus EBV[−]DLBCL: 38.9% [<italic>n</italic> = 14/36]; <italic>P </italic>=<italic> </italic>0.001). The results of the present study suggest that activation of the JAK‐STAT and NF‐κB pathways was characteristic of EBV(+)DLBCL‐E, which may reflect the nature of EBV‐positive tumor cells. Targeting these pathways as therapies might improve clinical outcomes of EBV(+)DLBCL‐E.</p> </abstract> … (more)
- Is Part Of:
- Cancer science. Volume 105:Issue 5(2014:May)
- Journal:
- Cancer science
- Issue:
- Volume 105:Issue 5(2014:May)
- Issue Display:
- Volume 105, Issue 5 (2014)
- Year:
- 2014
- Volume:
- 105
- Issue:
- 5
- Issue Sort Value:
- 2014-0105-0005-0000
- Page Start:
- 537
- Page End:
- 544
- Publication Date:
- 2014-04-09
- Subjects:
- Cancer -- Periodicals
Neoplasms -- Periodicals
Research -- Periodicals
Electronic journals
616.994005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1347-9032;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cas.12389 ↗
- Languages:
- English
- ISSNs:
- 1347-9032
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.603000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3168.xml